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Summary
 
Soluble cytokine receptors modulate the activity of their cognate ligands. Interleukin (IL)-6 in
association with the soluble IL-6 receptor (sIL-6R) can activate cells expressing the gp130 sig-
nal transducer lacking the specific IL-6R. To investigate the function of the IL-6–sIL-6R com-
plex in vivo and to discriminate the function of the IL-6–sIL-6R complex from the function of
IL-6 alone, we have established a transgenic mouse model. Double-transgenic mice coexpress-
ing IL-6 and sIL-6R were generated and compared with IL-6 and sIL-6R single-transgenic
mice. The main phenotype found in IL-6–sIL-6R mice was a dramatic increase of extramedul-
lary hematopoietic progenitor cells in liver and spleen but not in the bone marrow. In IL-6 sin-
gle-transgenic mice and sIL-6R single-transgenic mice no such effects were observed. The
high numbers of hematopoietic progenitor cells were reflected by a strong increase of periph-
eral blood cell numbers. Therefore, activators of the gp130 signal transducer like the IL-6–IL-6R
complex may represent most powerful stimulators for extramedullary hematopoietic progenitor
cells. gp130 activators may become important for the expansion of hematopoietic progenitor
cells in vivo and in vitro.
 
I
 
L-6 is a mediator of hematopoietic cell growth and dif-
ferentiation acting on B cells, T cells, keratinocytes, neu-
ronal cells, osteoclasts, and endothelial cells (for reviews,
see references 1 and 2). In the liver, IL-6 modulates the
transcription of acute phase response genes during acute and
chronic inflammatory states (3).
The IL-6–type cytokine family comprises IL-6, IL-11,
ciliary neurotrophic factor (CNTF)
 
1
 
, leukemia inhibitory
factor (LIF), oncostatin M (OSM), and cardiotrophin-1 (CT-
1). The biological action of these cytokines is mediated by
multisubunit cell surface receptors that share a common
signaling subunit, the gp130 signal-transducing molecule
(4, 5). The subunits of these receptors are members of the
cytokine/growth hormone receptor family that have con-
served cysteine and tryptophane residues in the extracellu-
lar domain and that signal via the JAK–STAT pathway (6–8).
IL-6 and IL-11 use a gp130 homodimer and OSM, CNTF,
LIF, and CT-1 use a heterodimer of gp130 and the 190 kD
LIF receptor for the activation of intracellular signaling cas-
cades (4). The receptor signaling complexes for CNTF, IL-6,
IL-11, and probably CT-1 (9) contain an additional ligand
specific subunit that is not required for LIF and OSM bind-
ing. Recently, a separate OSM-specific receptor has been
identified that also forms a heterodimer with gp130 (10).
Many soluble receptors (sR), like TNF-R, IL-1R, and
IL-4R, act antagonistically, competing with membrane recep-
tors for the binding of the cytokines (11–13). However, some
agonistic cytokine–sR complexes stimulate signal-transducing
receptors, rendering cells sensitive to the respective cyto-
kines that lack specific cytokine receptors on their surface.
Such cells on their own would not be able to respond to
the respective cytokine alone. This pathway, recently termed
transignaling, is used by the cytokines of the IL-6 family
(14, 15).
On target cells, IL-6 first binds to a specific IL-6 receptor
(IL-6R
 
a
 
) (16). This IL-6–IL-6R complex induces the ho-
modimerization of two gp130 molecules (17, 18), leading
to intracellular signaling events. Soluble forms of the IL-6R
complex are generated by limited proteolysis from the cell
surface (19, 20). Elevated concentrations can be found in
inflammatory diseases (21–24). In vivo, the sIL-6R acts as a
serum-binding protein for IL-6 and prolongs the plasma
 
1
 
Abbreviations used in this paper:
 
 CNTF, ciliary neurotrophic factor; CT-1,
cardiotrophin-1; LIF, leukemia inhibitory factor; OSM, oncostatin M;
PEPCK, phosphoenolpyruvate carboxykinase; sIL-6R, soluble interleu-
kin-6 receptor; TNF-R, tumor necrosis factor receptor.
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half life of IL-6 (25). However, the biologic function of the
IL-6–IL-6R complex in vivo is unknown.
To discriminate between biological functions of IL-6
alone and those of the IL-6–IL-6R complex, double-trans-
genic mice coexpressing human IL-6 and the human solu-
ble IL-6R (IL-6–sIL-6R mice) were generated and com-
pared with sIL-6R (25) and IL-6 (26) single-transgenic
mice and nontransgenic littermates. There were striking
differences regarding the phenotypes of single and double-
transgenic mice. IL-6–sIL-6R mice were smaller and dis-
played a marked hepatosplenomegaly caused by an extreme
expansion of extramedullary hematopoietic progenitor cells.
No such phenotype was observed in single-transgenic and
nontransgenic littermates. This study identifies the gp130
signal-transducing protein to be a most powerful mediator
of hematopoietic cell growth and differentiation in vivo.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
The generation of human sIL-6R
and human IL-6 transgenic mice has been described in detail else-
where (25, 26). By crossing homozygous sIL-6R and IL-6 mice,
hemizygous double transgenic mice (IL-6–sIL-6R mice) were gen-
erated that coexpressed both transgenes. Expression of the sIL-6R
transgene was driven by the neonatal phosphoenolpyruvate car-
boxykinase (PEPCK) promoter, which is transcriptionally acti-
vated at day 3 after birth and does not produce intrauterine devel-
opmental effects (25). The IL-6 transgene was driven by the
murine metallothionein-1 promoter (26). Serum concentration of
IL-6 ranged between 10 and 20 ng/ml in IL-6 and IL-6–sIL-6R
mice; concentrations of sIL-6R ranged between 4 and 8 
 
m
 
g/ml
in sIL-6R and IL-6–sIL-6R mice (data not shown).
 
Antibodies.
 
The following antibodies were used: anti-Gr-1
(RB6-8C5), Mac-1 (M1/70), B220 (RA3-6B2), CD4 (H129.19),
CD8a (53-6.7) (all PharMingen, San Diego, CA). mAbs were used
as lineage markers. Anti-c-kit (2B8) and Sca-1 (E13-161.7) (both
PharMingen) were used as hematopoietic stem cell markers. FITC-
or PE-conjugated antibodies were used.
 
Cell Sorting and Flow Cytometric Analysis.
 
Freshly isolated spleen,
liver, and bone marrow cells were obtained according to methods
previously described (27). Cells were washed three times with
RPMI 1640 medium and suspended at a concentration of 2 
 
3
 
10
 
5
 
 cells/ml of PBS containing 2.5% FCS and 0.05% sodium
azide before use. Double staining using anti-CD45 (30F11.1)
(PharMingen) mAbs and various lineage and hematopoietic stem
cell–specific mAbs was performed. The cell suspensions were in-
cubated for 30 min on ice with mAbs against cell surface mole-
cules in PBS containing 2.5% FCS and washed three times with
the same buffer. The fluorescence of the cells were examined us-
ing a FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA).
 
Organ Weight Recording and Histomorphological Analysis.
 
At ages
indicated in the figures, three mice each of single-transgenic and
nontransgenic littermates and IL-6–sIL-6R mice were sacrificed,
and liver, spleen, and total body weights were recorded. Mean
values of the ratio of organ weight:body weight are shown. Or-
gans were fixed in 4% formaldehyde/PBS and embedded in par-
affin. 5-
 
m
 
m sections were stained with haematoxylin–eosin.
 
Immunohistochemistry.
 
Immunohistochemistry was performed
using the indirect peroxidase staining method. Rat anti–mouse
Ly-6, rat anti–mouse CD3, rat anti–mouse B220, (PharMingen),
and rat anti–mouse Ia (Boehringer Mannheim, Germany) were
used as primary antibodies. As a secondary antibody, peroxidase-
conjugated goat anti–rat IgG (H
 
1
 
L) (Dianova, Hamburg, Ger-
many) was used.
 
In Vitro Colony-forming Assays.
 
The number of hematopoietic
progenitor cells was determined in clonogenic assays as described
previously (28). Cell samples were obtained from femurs and sus-
pensions of spleen and liver derived from one individual animal at
the age of 8–12 wk. The culture mixture for the assays consisted
of 0.8% methyl cellulose, 1% BSA, 10% FCS, 5% human plasma
and growth factors. Cells were seeded in agar cultures at a con-
centration of 10
 
4
 
/well, and CFU-GM and BFU-E were stimu-
lated with G-CSF (50 ng/ml) plus murine IL-3 (300 U/ml) or
stem cell factor (150 ng/ml) plus IL-3 plus erythropoietin (2 U/ml),
respectively. The total number of colonies per organ was calcu-
lated using the cellularity obtained for each organ and for the
bone marrow, assuming that each femur represents 6% of the to-
tal marrow.
 
Peripheral Blood Counts.
 
In general anesthesia, blood was ob-
tained by cardiac puncture and analyzed in a CellDyn 3500 hemo-
counter (Abbott, Delkenheim, Germany).
 
Results
 
IL-6–sIL-6R Mice Are Smaller and Have a Reduced Body
Weight.
 
The IL-6 transgene expression was regulated by
the mouse metallothionein-1 promoter. The sIL-6R trans-
gene expression was driven by the rat PEPCK promoter,
which acts neonatally and permits evaluation of the influence
of gene products after birth without intrauterine develop-
mental effects. A distinct phenotype was observed in IL-6–
sIL-6R mice compared with single-transgenic mice: IL-6 and
sIL-6R single-transgenic and nontransgenic littermates (Fig.
1 
 
A
 
, 
 
left
 
; data not shown) developed normally with respect to
weight gain, food and water intake, appearance, and behavior.
However, IL-6–sIL-6R mice (Fig. 1 
 
A
 
, 
 
right
 
) were remark-
ably smaller compared with single-transgenic and nontrans-
genic littermates. When body weights were measured over
a period of 20 wk, it became evident that the IL-6–sIL-6R
mice developed reduced body weights as soon as 6 wk after
birth (Fig. 1 
 
B
 
). At the age of 20 wk, mean values obtained
in IL-6–sIL-6R mice were around 20–25 g compared with
40 g in single-transgenic and nontransgenic littermates (Fig.
1 
 
B
 
). Moreover, at autopsy and at histopathological analy-
sis, IL-6–sIL-6R mice were found to have markedly re-
duced body fat in all regions of the organism compared
with single-transgenic littermates (data not shown).
 
Massive Increase of Liver and Spleen Weight in IL-6–sIL-6R
Mice.
 
Most remarkably, at the age of 4–6 wk, IL-6–sIL-
6R mice displayed distended abdominal regions (Fig. 1 
 
A
 
).
Single-transgenic and nontransgenic littermates were nor-
mal in this respect. The abdominal distension was caused by a
marked increase of liver and spleen weights relative to the
total body weight. Time course experiments (Fig. 2, 
 
A
 
 and
 
B
 
) revealed steadily increasing relative liver and spleen
weights in IL-6–sIL-6R mice, while the respective relative
organ weights in single-transgenic and nontransgenic litter-
mates were unchanged. At wk 20, the relative liver weight
(Fig. 2 
 
A
 
) had duplicated and the relative spleen weight
(Fig. 2 
 
B
 
) had increased by a factor of 5 when compared
with single-transgenic and nontransgenic littermates. 
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Figure 1. Weight abnormalities in IL-6–sIL-6R mice. (A) An IL-6–
sIL-6R double-transgenic mouse on the right side and a sIL-6R single-
transgenic mouse on the left side at the age of 8 wk. (B) Total body
weight recorded of IL-6–sIL-6R mice, of single-transgenic mice, and of
nontransgenic littermates. 
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The gross morphology of livers and spleens were exam-
ined in mice at 8 wk of age (Fig. 2 
 
C
 
). Livers and spleens of
8-wk-old IL-6R mice (Fig. 2 
 
C
 
, 
 
left
 
) and IL-6 mice and non-
transgenic littermates (data not shown) were completely nor-
mal. Livers of 8-wk-old IL-6–sIL-6R mice (Fig. 2 
 
C
 
, 
 
right
 
),
however, appeared dark in color and had a rugged and
humpy surface. This appearance was caused by round, whit-
ish, and with respect to the liver surface elevated foci. The
spleens of IL-6–sIL-6R mice were clearly enlarged in size
(Fig. 2 
 
C
 
, 
 
right
 
). The enlargement of the spleen is even more
Figure 2. Organ weight and gross morphology of liver and spleen. Liver (A) and spleen (B) weight of IL-6–sIL-6R, IL-6, and sIL-6R mice and non-
transgenic littermates. Organ weight is presented as liver weight/total body weight and spleen weight/total body weight, respectively. Gross morphology
of livers and spleens of sIL-6R mice (C, left) and IL-6–sIL-6R mice (C, right) at 12 wk of age. 
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Figure 3. Histomorphological analy-
sis of livers and spleens in IL-6–sIL-6R
(A–D), and IL-6 (A9–D9) mice. (A)
Liver tissue with several hematopoietic
foci containing predominantly granu-
lopoietic precursor cells and terminally
differentiated segmental granulocytes
(IL-6–sIL-6R, 8 wk). (A9) Normal liver
tissue with absence of hematopoietic
foci in an 8-wk-old IL-6 transgenic
mouse. (B) Spleen tissue with activated
extramedullary hematopoiesis showing
enlarged granulopoietic and erythropoi-
etic areas as well as increased number of
megakaryocytes (IL-6–sIL-6R, 8 wk).
(B9) Spleen tissue from an IL-6 trans-
genic mouse at 8 wk showing regular
distribution of red and white pulp and
little hematopoiesis. (C) Liver tissue
with large hematopoietic focus display-
ing blastic precursor cells and terminally
differentiated granulocytes (IL-6–sIL-
6R, 16 wk). (C9) Liver tissue from an
IL-6 transgenic mouse at 16 wk with
periportal plasmacytoma infiltrate. (D)
Spleen tissue with destroyed architecture
and complete involvement by hemato-
poiesis (IL-6–sIL-6R, 16 wk). (D9)
Spleen  tissue completely infiltrated by
plasmacytoma (IL-6, 16 wk). The scale
bars indicate 100 mm. 
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remarkable in light of the fact that IL-6–IL-6R mice had half
the body weight of single-transgenic and nontransgenic lit-
termates (see Fig. 1 
 
B
 
).
 
Increase of Liver and Spleen Weight in IL-6–sIL-6R Mice Is
Caused by Extramedullary Hematopoiesis.
 
The increase of liver
and spleen weight in IL-6–sIL-6R mice was caused by a
marked extramedullary proliferation of hematopoietic cells in
both organs (Fig. 3, 
 
A–D
 
), which was not detected in any
other parenchymal organ. No extramedullary hematopoie-
sis was found in single-transgenic and nontransgenic litter-
mates (Fig. 3, 
 
A
 
9
 
–
 
D
 
9
 
; data not shown). In the livers and
spleens of IL-6–sIL-6R mice, multiple hematopoietic foci
were present, which increased in size with time. At 8 wk,
there were occasional foci (Figs. 3, 
 
A
 
 and 
 
B
 
) present in both
Figure 4. Immunohistochemical
analysis of the Ly-6 (A–C), and
Ia (A9–C9) surface protein ex-
pression on hematopoietic liver
cells in IL-6–sIL-6R double-trans-
genic mice. Granulocytic (A) and
monocytic/macrophage (A9) cells
are almost completely absent in
the liver at the age of 4 wk. At 6
wk, scattered granulocytic (B)
and small clusters of monocytic/
macrophage cells (B9) appear in
the liver, representing early he-
patic extramedullary hematopoie-
sis. At the age of 12 wk, there are
large confluent hepatic foci show-
ing predominantly granulopoie-
tic differentiation (C), but also
significant monopoietic cells (C9).
The scale bars indicate 100 mm. 
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organs. However, at 16 wk, complete involvement of liver
and spleen with multiple and large confluent hematopoietic
foci accompanied by loss of the parenchymal organ archi-
tecture was demonstrated (Fig. 3, 
 
C
 
 and 
 
D
 
). Determination
of enzymatic values in the serum (LDH, alkaline phospha-
tase, and transaminases) did not show any alteration either
in IL-6–sIL-6R mice or in single-transgenic and nontrans-
genic littermates (data not shown), indicating that the liver
function of the mice was not compromised.
Also, a large number of megakaryocytes was detected in
IL-6–sIL-6R mice (Fig. 3, 
 
B
 
 and D) but not in single-trans-
genic and nontransgenic littermates (Fig. 3, A9–D9). Remark-
ably, megakaryocytes were present only in the spleen (Fig.
3, B and D) and not in the liver (Fig. 3, A and C). Megakary-
ocytes were found as soon as the age of 8 wk (Fig. 3 B) and
further increased in number at the age of 16 wk (Fig. 3 D).
Plasmacellular infiltrates in the liver and spleen with con-
secutive involvement of all parenchymal organs were ob-
served in 50% of both IL-6 (Fig. 3, C9 and D9) and IL-6–
sIL-6R mice (data not shown) around the age of 16 wk. In
IL-6 single-transgenic animals, plasmacellular infiltrates were
the only histopathological abnormalities detected. However,
in IL-6–sIL-6R mice, extramedullary hematopoiesis (Fig. 3,
A–D) was the most dominant histopathological finding ob-
served in all mice examined.
These results clearly demonstrate that the presence of the
IL-6–sIL-6R complex leads to extramedullary accumulation
of hematopoietic progenitor cells, which are unresponsive
to IL-6 alone.
Characterization of Hematopoietic Cells by Immunohistochem-
istry and FACSÒ Analysis. To characterize further the na-
ture of the hematopoietic cells in the liver, immunohis-
tochemistry was performed with antibodies to surface antigens
of neutrophils (Ly-6), monocytes/macrophages (Ia), B cells
(B220), and T cells (CD3). As early as 4 wk after birth, IL-6–
sIL-6R mice showed single positive neutrophils (Fig. 4 A)
and monocytes/macrophages (Fig. 4 A9) in the liver. At the
age of 6 wk, there were increased numbers of scattered
neutrophilic granulocytes (Fig. 4 B) and small clusters of
monocytic cells (Fig. 4 B9) present in the liver. Large con-
fluent foci of both cell types were detected at the age of 16 wk
(Figs. 4, C and C9). Immunohistochemistry using antibod-
ies directed against B and T cell epitopes revealed that B cells
were also present, but to a lesser extent, and that T cells were
absent (data not shown). In single-transgenic and nontrans-
genic littermates, immunohistochemistry using the above
mentioned antibodies gave negative results (data not shown).
Cells harvested from liver, spleen, and bone marrow
from single-transgenic and nontransgenic littermates and
from IL-6–sIL-6R mice were subjected to FACSÒ analysis
to determine the percentage of macrophages, granulocytes,
progenitor cells, and B and T lymphocytes present in these
organs. In the bone marrow, there were no significant dif-
ferences detected between IL-6–sIL-6R mice and single-
transgenic and nontransgenic littermates with respect to the
various surface antigens tested (data not shown). In the
spleen of IL-6–sIL-6R mice (Table 1, upper panel), the num-
ber of granulocytes, macrophages, and Sca-11 progenitor
cells increased by a factor of 2.3, 1.5, and 2, respectively,
compared with single-transgenic or nontransgenic litter-
mates. B cells were increased 2.3-fold in both IL-6 single-
transgenic and in IL-6–sIL-6R mice compared with non-
transgenic littermates. CD41 and CD81 lymphocytes were
not different among the groups of mice tested.
The most prominent findings were seen in the liver of
IL-6–sIL-6R mice (Table 1, lower panel). Granulocytes, mac-
rophages, Sca-11 progenitor cells, and B cells were absent
or present only scarcely in single-transgenic sIL-6R mice
and nontransgenic littermates. Macrophages and B cells were
increased 15-fold and 45-fold in IL-6 single-transgenic
mice, respectively, compared with sIL-6R single-transgenic
or nontransgenic littermates. All cell lines (granulocytes,
macrophages, progenitor cells, and B cells) were increased
by a factor of 200–300 in IL-6–sIL-6R mice compared with
IL-6R single-transgenic or nontransgenic littermates.
These results show that hematopoietic cells in the liver
and spleen of IL-6–sIL-6R mice were mainly granulocytes
and monocytes, to a lesser extent B cells, and not T cells.
Massive Hematopoietic Progenitor Cell Proliferation in the Liver
and Spleen. In view of the extramedullary hematopoiesis
observed in liver and spleen, we investigated whether the
continuous stimulation of the gp130 signal transducer af-
fected committed hematopoietic progenitor cells of the
granulocytic–monocytic and erythocytic lineages in differ-
ent hematopoietic organs. The frequency of hematopoietic
progenitor cells in the bone marrow, spleen, and liver of
transgenic and nontransgenic mice was determined using in
vitro clonogenic assays. The IL-6–sIL-6R-mediated gp130
stimulation had distinct effects on different hematopoietic
lineages in extramedullary organs: the total number of
CFU-GM and BFU-E in spleen and liver derived from
IL-6–sIL-6R mice was increased ten times when compared
Table 1. Distribution of Phenotypes of Hematopoietic Cells 
Isolated from the Spleen and Liver
Organ
Mice
Marker Nontransgenic sIL-6R IL-6 IL-6–sIL-6R
Spleen GR1 10.0 10.5 10.7 23.6
MAC-1 12 14 6.7 21.6
SCA-1 20 21 23.4 42
B220 14 15 35 36
CD8 2.15 2.11 2.34 3.2
CD4 6.8 8.8 3.8 5.8
Liver GR1 0.003 0.004 2 1.14
MAC-1 2 0.006 0.08 1.04
SCA-1 22 2 0.932
B220 0.001 0.002 0.09 0.665
Freshly isolated cells obtained from organs as indicated in the table were
subjected to FACSÒ analysis. Values are expressed as total numbers of cells
3 106 per organ. One representative experiment out of three is shown.762 gp130 Activation and Extramedullary Hematopoiesis
with IL-6–sIL-6R single-transgenic mice and nontrans-
genic littermates (Fig. 5, A and B). Most interestingly, in
the bone marrow, the relative and absolute number of clo-
nogenic hematopoietic cells was not elevated in IL-6–sIL-
6R mice compared with IL-6 and sIL-6R single-transgenic
and nontransgenic mice (Fig. 5 C).
These data show that continuous gp130 activation leads
to a massive increase of extramedullary committed hemato-
poietic progenitor cells and not to an increase of bone mar-
row–derived progenitor cells.
Extramedullary Hematopoietic Progenitor Cells Are Function-
ally Normal. Peripheral blood cell numbers were deter-
mined at the age of 8, 16, and 24 wk in IL-6–sIL-6R mice
and compared with numbers measured in IL-6 and sIL-6R
single-transgenic mice and nontransgenic littermates. Whereas
the peripheral blood cell numbers of single-transgenic and
nontransgenic littermates were unchanged over the period
of time tested, a most dramatic increase of white blood cells
consisting mainly of neutrophilic granulocytes was observed
in IL-6–sIL-6R mice (Fig. 6, A and B). At the age of 8 wk,
there was no difference observed between IL-6–sIL-6R
mice and single-transgenic mice and nontransgenic litter-
mates. However, at the age of 16 wk, white blood cells and
neutrophils increased by a factor of 10 and 17, respectively,
and at the age of 24 wk by a factor of 27 and 48, respec-
tively, in IL-6–sIL-6R mice. Platelets (Fig. 6 C), red blood
cells (Fig. 6 D), and hemoglobin values (Fig. 6 E) of IL-6–
sIL-6R mice increased by a factor of 2.1, 1.5, and 1.5, re-
spectively, when compared with age-matched nontrans-
genic littermates and did not change in 16- and 24-wk-old
mice. In single-transgenic animals, peripheral blood cell
counts and hemoglobin values were not altered compared
with nontransgenic mice (Fig. 6, C–E). Thus, the expanded
pool of hematopoietic progenitor cells in IL-6–sIL-6R mice
appears to retain its capacity to undergo proliferation and
differentiation into mature blood cells, resulting in expan-
sion of circulating blood cells.
Discussion
Our study demonstrates that the activation of the gp130
signal transducer by a complex of IL-6 and the sIL-6R rep-
resents a major stimulation of growth and differentiation of
hematopoietic progenitor cells in vivo. The presence of IL-6
alone is not sufficient to stimulate these cells. As demon-
strated by histomorphological and immunohistochemical data
and in vitro clonogenic assays, in IL-6–sIL-6R mice an ex-
pansion of hematopoietic progenitor cells of the granulo-
cytic–monocytic, megakaryocytic, and erythroid lineages was
observed.
We conclude that these hematopoietic progenitor cells
express gp130 signal-transducing molecules on their surface
and lack the specific IL-6Ra. This notion is underscored
by a recently published study using gp130-deficient mice,
which were shown to exhibit a greatly diminished number
of hematopoietic progenitor cells (29). Thus, gp130 activa-
tion is required to stimulate hematopoietic progenitor cells.
Because IL-6 and IL-11 act via a gp130 homodimer, loss of
IL-6 can be compensated by IL-11, possibly explaining
why IL-6–deficient mice are viable (30, 31). In mice over-
expressing cytokines like LIF (32) or OSM (33), requiring
the gp130/LIF-R heterodimer for signal transduction, he-
matopoietic effects are scarce, indicating that hematopoietic
progenitor cells express little or no LIF-R on their surface.
This hypothesis is supported by findings from mice in
which the LIF-R has been deleted by targeted disruption
(34). These mice show no significant abnormalities of the
hematopoietic system.
Figure 5. Evaluation of hematopoietic progenitor cells in the bone
marrow, spleen, and liver of transgenic mice and nontransgenic litter-
mates. Standard CFU-GM (open bars) and BFU-E (closed bars) assays were
performed using spleen (A), liver (B), or bone marrow (C) cells from ei-
ther IL-6–sIL-6R, IL-6, and sIL-6R mice or nontransgenic littermates, as
indicated in the figure. Triplicate cultures were scored after staining with
May-Grünwald-Giemsa (28) and are presented as mean values and stan-
dard deviation of one representative experiment out of three.763 Peters et al.
The fact that increased B cell numbers are detected in
spleen and liver of IL-6 and IL-6–sIL-6R transgenic mice
supports the notion that B cells express the specific IL-6R
on their surface and thus may be activated by IL-6 alone
(35). Accordingly, IL-6 induced plasmacytosis in IL-6 and
IL-6–sIL-6R mice by stimulating proliferation and matura-
tion of B cells (36, 37).
In IL-6–sIL-6R double transgenic mice a marked reduc-
tion of body weight and body size associated with a reduc-
tion of body fat was observed compared with single-trans-
genic and nontransgenic littermates. Currently, we can not
explain the reduced body size observed in these animals.
However, the reduced body fat that we observed in IL-6–
sIL-6R mice could be explained by the fact that the re-
cently identified leptin receptor (OB-R) (38) is a signal-
transducing protein similar to gp130, involving the same
intracellular signaling molecules (39, 40). The OB-R is lo-
cated in many tissues, including the hypothalamus, and is
Figure 6. Peripheral blood hematological data. White blood cell (A), neutrophil (B), platelet (C), red blood cell (D), and hemoglobin (E) values were
analyzed from six transgenic mice and nontransgenic littermates per group at ages indicated in the figure. Mean values with standard deviations are pre-
sented.764 gp130 Activation and Extramedullary Hematopoiesis
involved in the regulation of the size of adipose tissue mass
through effects on satiety and energy metabolism. The
natural ligand of the OB-R, leptin, a 16-kD protein, is ex-
pressed primarily in the white adipose tissue (41). It might be
possible that the IL-6–sIL-6R complex activates gp130 mole-
cules on OB-R–expressing cells, thereby activating leptin-
specific signaling pathways.
We have provided evidence that the IL-6–sIL-6R com-
plex in vivo induces extramedullary hematopoiesis in liver
and spleen but not in bone marrow. It is known that there
are resident hematopoietic stem cells in the adult liver (42).
These cells might be expanded after stimulation by IL-6–
sIL-6R in a concentration-dependent manner. Rather high
concentrations of IL-6 (2 nM) and sIL-6R (.20 nM) are
required for the activation of gp130-expressing cells in
vitro (43). This is somewhat surprising considering that the
KD of the IL-6–sIL-6R interaction is in the range of 1 nM
(16, 44). A possible explanation could be that the average
half-life of the IL-6–IL-6R complex is shorter than the
time required to assemble the functionally active IL-6–IL-
6R/gp130 complex. We have recently demonstrated that
the sIL-6R acts predominantly at the site of its generation
(M. Peters et al., submitted for publication). Because liver-
specific promoters drive the expression of the transgenes used
in the present study, one could reason that sufficient con-
centrations of IL-6 and sIL-6R required for an effective
stimulation of hematopoietic progenitor cells are found pre-
dominantly in the liver. Recently, transgenic mice coex-
pressing IL-6 and the membrane-bound IL-6R have been
generated (45) in which soluble IL-6R was generated by
shedding at levels 100-fold lower compared with IL-6–
sIL-6R mice of the present study. No hematopoietic ab-
normalities were found in these mice, indicating that high
levels of the IL-6–sIL-6R complex are required to stimu-
late hematopoietic progenitor cells.
Extramedullary hematopoiesis in the spleen has been rec-
ognized after administration of recombinant G-CSF to mice
(46). Splenic stimulation of progenitors in IL-6–sIL-6R
mice indicates that cytokines of the IL-6 family can con-
tribute to hematopoiesis in the spleen. Recently, it has
been demonstrated that LIF overexpression results in mod-
erate splenomegaly and slightly activated extramedullary
hematopoiesis (32, 47). LIF-deficient mice show a reduc-
tion of hematopoietic progenitors in the spleen and bone
marrow. However, hematopoietic spleen and bone mar-
row progenitor cells from those mice transplanted into le-
thally irradiated normal mice retained their normal function,
indicating that LIF is required in the microenvironment to
maintain stem cell numbers, rather than affecting the po-
tential of hematopoietic progenitors (48). In light of these
results, one might speculate, that similar to LIF, the IL-6–
sIL-6R complex contributes to the microenvironment re-
quired by hematopoietic cells in spleen and liver. How-
ever, it is of interest that stimulation by IL-6–sIL-6R leads
to far stronger hematopoiesis than stimulation by LIF.
It is possible that liver and spleen cells express other impor-
tant growth factors like stem cell factor (49, 50), chemo-
kines as pre-B cell–stimulating factor (51), or flt-3 (52), ei-
ther in membrane-bound or soluble form. These cytokines
might be involved as cofactors in the growth of hemato-
poietic progenitor cells in these organs.
Hematopoietic progenitor cells stimulated by the IL-6–
sIL-6R complex are functionally normal. This is reflected
by the highly elevated numbers of granulocytes, megakaryo-
cytes, and erythrocytes in the peripheral blood. Thus, the
expanded pool of hematopoietic progenitor cells appears to
retain its capacity to undergo proliferation and differentia-
tion into mature blood cells, resulting in expansion of cir-
culating blood cells.
In summary, there are three major findings of this study.
First, we provided evidence that continuous activation of the
gp130 signal transducer by molecules like the IL-6–sIL-6R
leads to a most effective stimulation of hematopoietic pro-
genitor cells. Progenitor cells of the granulocytic–monocytic,
megakaryocytic, and erythroid lines are involved. Second,
IL-6–sIL-6R causes a stimulation of predominantly extra-
medullary and not bone marrow hematopoietic progenitor
cells. Third, progenitor cells are functionally normal, re-
taining their capacity to undergo maturation into mature
blood cells. Apart from expanding CD341 cells obtained
from cord blood in vitro (43), continuous activation of the
gp130 signal transducer by agents like the hIL-6–hsIL-6R
complex could be the most effective mechanism to recon-
stitute hematopoiesis in vivo or ex vivo in patients with cy-
topenic conditions.
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